CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (BIND) announced today the closing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, resulting in gross proceeds of $70,500,000 before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Select Market under the ticker symbol BIND on September 20, 2013. Credit Suisse (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel Nicolaus & Company, Incorporated and JMP Securities LLC are acting as co-managers. A registration statement relating to these securities has been filed with, and was declared effective by, the U.S. Securities and Exchange Commission on September 19, 2013. The offering was made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the terms of the offering can be obtained by eligible investors from their Credit Suisse or Cowen and Company sales representative, or from the Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: 800-221-1037, Email: newyork.prospectus@credit-suisse.com and from Cowen and Company, LLC c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island … Continue reading →

Poway, California (PRWEB) September 24, 2013 Vet-Stem, Inc., the world's leading Regenerative Veterinary Medicine company, is pleased to announce that Pets Best Insurance plans provide coverage for Regenerative Stem Cell Therapy. Pets Best Insurance knows that with pets come vet bills, especially when a pet is suffering from the pain of injury or arthritis. Pets Best Insurance wants the best for pets and their owners and Vet-Stem offers the best in regenerative medicine for them. Pets suffering from pain of osteoarthritis, joint issues, and injuries of the muscle, tendon and ligament can now be given stem cell therapy. Vet-Stem first offered stem cell therapy for dogs and cats in 2007. One of the success stories and stem cell advocates is part of the Pets Best Insurance family, Jetta, owned by Greg McDonald, CEO of Pets Best Insurance. Jack L. Stephens, DVM and President/Founder of Pets Best Insurance talks about Gregs experience: "Our CEO had a wonderful experience utilizing Vet-Stem therapy in his twelve year old lab. He loved throwing, and she loved chasing, a ball every evening. But as she aged, she just could not do it due to severe arthritis. Surgery was not a viable alternative and he asked … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading →

Sep. 24, 2013 Scientists from King's College London have announced that 16 human embryonic stem (hES) cell lines have been approved by the US National Institutes of Health (NIH) and placed on their Stem Cell Registry, making them freely available for federally-funded research in the USA. The stem cell lines, which carry genes for a variety of hereditary disorders such as Huntington's disease, spinal muscular dystrophy and cystic fibrosis, are considered to be ideal research tools for designing models to understand disease progression, and ultimately in helping scientists develop new treatments for patients. King's is now one of the five biggest providers of disease-specific human embryonic stem cells lines on the NIH Registry, and the largest from the UK. The development is a significant milestone for King's and keeps the university at the forefront of global research into regenerative medicine. Embryonic stem cell lines are grown from frozen embryos donated by patients undergoing preimplantation genetic diagnosis (PGD) in conjunction with IVF treatment. Unlike 'adult' stem cells, embryonic stem cells can differentiate into any type of cell within the body and are considered to be more useful for stem cell-based therapies. Disease-specific stem cell lines are created from embryos found to … Continue reading →

MANILA, PhilippinesThe new Food and Drug Administration (FDA) guidelines regulating stem cell therapy in the Philippines are sorely inadequate and grossly misleading, according to a group of doctors. The Philippine College of Physicians (PCP), the umbrella organization of Filipino doctors specializing in internal medicine, said it was disappointed with the FDA and Department of Health for failing to decisively act on the dangers posed by unregulated stem cell therapy in the country. The recent guidelines released by the FDA fell short and will not stop the proliferation of stem cell therapy for ailments that were not subjected to scientific study or clinical trials, PCP president Prescilla Limpin said in a statement We will not back down from our earlier call and we will not stop until stem cell therapy undergoes scientific studies to prove its safety, quality and efficacy on the ailments it has been propagated. We will not allow its promotion and use to helpless and unknowing patients and their desperate families, said Dr. Prescilla Caguioa, the PCP president. The FDA guidelines require that all stem cell and cellular-based treatments offered in the country should first pass the agencys standards for safety, efficacy and quality. Beginning Sept. 1, 2013, … Continue reading →